The study, published in July 2025 in the journal Dystonia, is, according to its authors, the first report of advanced programming and lead revision surgery in GPi deep brain stimulation for DYT-11. That gap in the literature is itself telling. Because the condition is rare and because most published patients respond quickly to simple monopolar settings, clinicians have had almost no guidance for what to do when stimulation falls short. The meta-analytic literature on myoclonus dystonia is dominated by single-patient reports — the median number of patients per study in one analysis was just one — which makes the field especially vulnerable to publication bias toward success stories. The Florida team’s retrospective chart review of three patients offers a rare look at the troubleshooting playbook that usually stays inside the clinic.

The first patient, a 27-year-old woman with a family history of DYT-11 and a confirmed SGCE variant, had developed generalized myoclonus and cervical dystonia in early childhood and received bilateral GPi leads at age eighteen. Years later she arrived at the Fixel Institute with near-constant jerks and dystonic pain despite functioning hardware. Imaging-based lead localization showed her electrodes sat reasonably within the posteromedial GPi, but monopolar testing revealed narrow therapeutic windows: the currents needed to help her symptoms quickly triggered side effects, likely from current spreading into the adjacent internal capsule. Thirteen months of systematic programming — sweeping amplitudes, pulse widths, and frequencies, and trying bipolar configurations — failed to deliver satisfactory control of both her myoclonus and her dystonia.

The surgical team then did something that had never been documented for this disease: they replaced her leads. Three months after bilateral revision surgery with newer-generation electrodes, a single programming session resolved her dystonia-related pain and tension completely and significantly reduced her spontaneous myoclonus. The new leads were positioned lateral and ventral to the originals, which allowed the team to tolerate higher, more effective settings. The numbers are striking. On the Burke-Fahn-Marsden scale, her dystonia score in the stimulation-on state fell from 21 before revision to 1 at seven months, settling at 3 by thirteen months. What had been a near-failure of neuromodulation became, after a few millimeters of repositioning, a near-complete response.

The second case illustrates a different failure mode. A 30-year-old woman diagnosed in childhood had benefited rapidly from her original GPi implants, but her condition deteriorated precipitously and her device was explanted over concern for a hardware infection. When new leads were reimplanted, the benefit never fully returned. At the Florida center, testing showed low thresholds for side effects, and lead localization revealed that the replacement electrodes sat dorsal on the right and anteromedial on the left relative to the originals — subtly but meaningfully off target. Her programming had grown baroque, relying on interleaving, a technique that cycles two independent stimulation settings through the same lead, without perceived benefit. After a multidisciplinary evaluation, the team revised the leads again. Post-revision, she tolerated higher currents on simple monopolar settings; one year later she had no residual dystonia, and at 23 months her benefit was sustained with a United Dystonia Rating Scale score of 13, down from 25 before revision.

The third patient required no surgery at all, only persistence at the programming console. A 75-year-old woman with a decades-long history of tremor, dystonia, and myoclonus, diagnosed late in life through genetic testing, underwent staged bilateral GPi implantation. In the operating room, stimulation at her most ventral contact actually worsened her myoclonus — an early warning that standard settings would not suffice. Simple configurations and pulse width adjustments failed, and raising amplitude brought benefit only at the cost of capsular side effects. The breakthrough came through increasingly complex configurations: double monopolar settings improved her myoclonus, and a three-contact bipolar arrangement unlocked further amplitude tuning. Six months after her second lead was placed, her Toronto Western Spasmodic Torticollis Rating Scale score had fallen from 38 to 14; at twelve months it was 7, and at 33 months she reported no residual disability.

Beyond the clinical narratives, the study contributes something more novel: brain recordings from inside the patients’ own stimulators. All three were implanted with sensing-enabled pulse generators that capture local field potentials, or LFPs — the summed electrical chatter of neurons near the electrode contacts. The team extracted 30-second resting recordings, computed power spectra using Welch’s method, and normalized the features with the FOOOF technique, which separates periodic oscillations from the background aperiodic signal. Across the group, effective stimulation and optimization were accompanied by statistically significant reductions in both low beta power, spanning roughly 12 to 20 hertz, and high beta power, from 20 to 30 hertz, with p-values of 0.02 and below 0.001 respectively. In each patient, broadband beta activity that had been prominent before revision or optimization diminished once the therapy was working.

That observation matters because beta oscillations in the pallidum are an emerging, if contested, biomarker in the dystonia field. In Parkinson’s disease, excessive beta activity in the motor circuitry is a well-established target of stimulation, and some programmers have begun using beta suppression as feedback for tuning settings. In dystonia, the picture is murkier: some studies link low-frequency pallidal oscillations to involuntary muscle activity, while others argue that beta power is not elevated in heterogeneous dystonia populations — one small study even used dystonia patients as the control group for studying beta bursts in Parkinson’s disease, on the assumption they would show no elevation. The Florida team suggests that beta activity may play an underrecognized role in genetic dystonia specifically, but they are careful to flag the caveat that their cohort numbers three patients and requires confirmation in larger samples. Prior LFP work in myoclonus dystonia has been limited to a single artifact-reduction paper involving three patients, none with confirmatory genetic data.

The practical lessons the authors draw are as valuable as the electrophysiology. Their troubleshooting algorithm starts with a monopolar review; if side effect thresholds are uniformly below 3 milliamperes at a 90-microsecond pulse width and 130 hertz, they suspect the lead cannot deliver enough energy to treat dystonia, and they escalate methodically — amplitude first, then pulse width, then frequency, then bipolar and directional configurations, reserving interleaving and cycling for patients who initially respond and then lose benefit. They also emphasize a phenomenological pitfall: myoclonus tends to respond faster and more completely than dystonia, so clinicians may mistake adequate myoclonus control for overall success and accept suboptimal dystonia improvement. Setting expectations — that dystonia relief may take months — is framed as central to patient satisfaction.

For a disease this rare, three carefully documented cases can reshape practice. The series demonstrates that a suboptimal response to deep brain stimulation in DYT-11 is not necessarily the end of the road: lead position, side effect thresholds, and programming complexity all offer levers, and modern sensing devices may eventually guide those adjustments with physiological feedback rather than trial and error. The authors call for future work characterizing the electrophysiology and brain connectomics of DYT-11, and for studies of how lead location relates to biomarkers of response. Until then, their message to clinicians is quietly radical for a field accustomed to easy wins: in myoclonus dystonia, the first setting is often not the best setting, and the tools to fix a struggling stimulator already exist.

Subject of Research: Troubleshooting pallidal deep brain stimulation, including lead revision and advanced programming, in genetically confirmed DYT-11 myoclonus dystonia

Article Title: Challenges in deep brain stimulation for DYT-11: a single center troubleshooting experience

Article References: Remz, M. A., Garg, V., Johnson, K. A., Au, K. L. K., Babajani-Feremi, A., Lavu, V. S., de Hemptinne, C., & Wong, J. K. (2025). Challenges in deep brain stimulation for DYT-11: a single center troubleshooting experience. Dystonia, 4, Article 14485. https://doi.org/10.3389/dyst.2025.14485

Image Credits: AI Generated

DOI: 10.3389/dyst.2025.14485

Keywords: deep brain stimulation, DYT-11, myoclonus dystonia, SGCE gene, globus pallidus, lead revision, local field potentials, beta oscillations, dystonia, neuromodulation, programming, Challenges